19.11.2015

ARS submitted a clinical trial application package for approval by the Russian regulatory authorities of an open label, randomized, crossover, two-sequence, two-period comparative study of pharmacokinetics and bioequivalence of the generic of one of the fastest growing public listed pharmaceutical companies in India.